A branded generic is the trade name specified to a drug which is bio-equivalent to the first manufacturer. Branded generics provides drug manufacturers a chance to discover better approaches to figure drugs which have lost patent safety as well as gone generic, in addition to this some are producing a significant package in the process. FDA directions regard branded generics the same as branded drugs.
The worldwide market for branded generics accounted for approximately US$ 190 Billion in 2016 and is now likely to register CAGR of 7.3% during the assessment period of 2016–2026 to reach a market value of over US$ 410 Billion by 2026.
The worldwide market categorized on the basis of formulation type includes parenteral, oral, topical and others.
The overall market categorized on the basis of drug class includes antimetabolites, alkylating agents, anti-hypertensive, hormones, anti-depressants, lipid-lowering drugs, anti-epileptics, anti-psychotics and others. Based on the distribution channel, the worldwide market is categorized into drug stores, online pharmacies, retail, pharmacies and hospital pharmacies.
Based on the therapeutic application, the overall market is categorized into cardiovascular diseases, oncology, neurology, analgesics and anti-inflammatory, diabetes, dermatology diseases, gastrointestinal diseases and others. The cardiovascular diseases category accounted for about 11.8% of the overall market share through the end of the year 2016 and was likely to account for a value of about US$ 25 Billion by 2016. The category is predicted to be the most leading category over the calculated period and will be registering the maximum 8.2% CAGR in valuation terms throughout 2016-2026. The dermatology diseases category is expected to grow at a 6.0% CAGR in terms of revenue during the assessment period. The dermatology and neurology diseases categories are anticipated to be the least attractive categories in the worldwide market for branded generics in terms of revenue. The diabetes category is anticipated to account for a 7.7% CAGR in revenue terms over the conjecture time frame of 2016 to 2026 to account for a figure of about US$ 45 Billion through 2026. The Oncology category is likely to account for a 6.9% CAGR in revenue terms during the calculated time frame to account for a figure of over US$ 30 Billion throughout 2026. The Neurology category is likely to account for a 6.1% CAGR in revenue terms during the considered time frame to account for a figure of around US$ 25.0 Billion by 2026. The anti-inflammatory and analgesics category is anticipated to account for a 6.6% CAGR in revenue terms during 2016-2026 to account for a figure of about US$ 30 Billion by 2026.
The overall market for branded generics is studied across seven prominent regions, namely Latin America, North America, Eastern Europe, Western Europe, MEA, APEJ and Japan. Some of the emerging and the most lucrative regions in the branded generics market are India, Russia, Brazil and China.
Queries regarding these research findings can be addressed to Future Market Insights’ analysts at firstname.lastname@example.org